Trial Profile

An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipifarnib (Primary)
Indications Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Peripheral T-cell lymphoma
Focus Proof of concept; Therapeutic Use
Acronyms PTCL
Sponsors Kura Oncology

Most Recent Events

14 Dec 2021 Final Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
13 Dec 2021 According to a Kura Oncology media release, Thomas Witzig is the study's lead investigator.
13 Dec 2021 Results published in the Kura Oncology Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com